Melanoma Treatment Market (Therapeutics) Worth $3.6 Billion in 2020

May 19, 2015, 09:00 ET from RnR Market Research

DALLAS, May 19, 2015 /PRNewswire/ --

This melanoma treatment market (therapeutics) report analyzes treatment usage patterns, drug types available and pipeline and market forecasts across indications for melanoma with a multi-scenario forecast data to 2020.

Complete report on melanoma treatment market (therapeutics) spread across 189 pages supported with 23 tables and 50 figures is now available at .

The report on melanoma treatment market titled "Melanoma Therapeutics Market to 2020 Rising Prevalence and Evolving Treatment Algorithms to Drive Market Growth" talks in-depth about Melanoma, which is a highly heterogeneous disease comprising Cutaneous Melanoma (CM), Ocular Melanoma (OM), Mucosal Melanoma (MM), melanoma of the internal organs, and, according to some classifications, melanoma of the soft parts (non-bony and non-cartilaginous tissues) of the body. CM is by far the most common form of melanoma, accounting for approximately 90-95% of all melanomas.

Rapid melanoma treatment market growth is also anticipated over the forecast period due to the expanding melanoma treatment population and the continued uptake of recently approved drugs. The melanoma pipeline is currently strong, with several promising molecules in development including, Polynoma's seviprotimut-L, Amgen's talimogene laherparepvec (T-VEC) and Roche and Genentech's cobimetinib in combination with Zelboraf, which are in development for CM, as well as AstraZeneca's selumetinib which is in development for OM. Consequently, the melanoma therapeutics market is projected to grow from $1.3 billion in 2013 to $3.6 billion in 2020, at a CAGR of 15.4%.

The melanoma treatment segments discussed in this research include Adjuvant Therapy for CM (All Mutations), Advanced Therapy for CM (All Mutations) and Advanced Therapy for CM (BRAF Mutated Patients Only). Order a copy of this report at .

Historically, melanoma has been considered as a very challenging disease to treat with pharmacotherapy. However, in recent years, understanding of the pathophysiology and heterogeneity of melanoma, and particularly CM, has developed considerably. This has led to the approval of several new drug agents indicated for CM since 2011, namely Sylatron (peginterferon alfa-2b), Yervoy (ipilimumab), Opdivo, (nivolumab), Keytruda (pembrolizumab), Zelboraf (vemurafenib), Tafinlar (dabrafenib) and Mekinist (trametinib). These drugs have dramatically improved the treatment options for CM patients, leading to unprecedented market growth.

The report on Melanoma Therapeutics Market to 2020 covers and includes an introduction to the melanoma indication, including disease symptoms, epidemiology, etiology, pathophysiology, staging, diagnosis and treatment. It also provides an in-depth analysis of the current melanoma marketed products landscape including product profiles of the main drugs used in melanoma and heat maps that compare safety and efficacy parameters of the various drugs. Comprehensive analysis of the melanoma pipeline by phase of development, molecule type, molecular target and novelty along with a comparative analysis of late-stage pipeline drugs that are likely to enter the market in the forecast period is also provided alongside heat maps has been covered. Additional in-depth analysis of melanoma clinical trials by size, duration, failure rates and primary and secondary endpoints, Multi-scenario forecast data for the market to 2020, taking into account how it will be affected by the introduction of new drugs and changes in disease epidemiology across the key developed markets, the US, Canada, the UK, France, Germany, Italy, Spain and Japan and Discussion of the licensing and co-development strategic consolidations landscape in melanoma, by Phase of development and molecule type, as well as an analysis of both licensing and co-development deals by year, and network maps of licensing and co-development deals are also provided in this research.

This research on melanoma treatment market (therapeutics) will assist business development and enable marketing executives to strategize their product launches, by allowing them to gain a comprehensive understanding of the melanoma indication including segmentation of disease and treatment algorithms. It also helps understand the current melanoma marketed products landscape and recognize the dominant therapeutic agents and pharmaceutical players involved. Identifying trends and developments within the melanoma pipeline including which molecule types and molecular targets are prominent becomes easier while considering market opportunities and potential risks by examining trends in melanoma clinical trial duration and size, as well as clinical trial failure rates, amongst clinical trial Phases and molecule types. The report also helps assess the potential clinical and commercial impact of current late-stage pipeline molecules on the melanoma therapeutics market.

The tables provided in this melanoma therapeutics market report include:

Characteristics of Types of Melanoma 13
Staging of Cutaneous Melanoma 24
Melanoma Clinical Trial Endpoint Definitions 34
Melanoma Therapeutics Market, Global, Pipeline, Groups of Molecular Targets, 2014 77
Breakdown of ‘Other' Molecular Targets 147
Breakdown of Molecular Target Combinations 148
Melanoma Therapeutics, Global, All Pipeline Products, Discovery Phase, 2014 149
Melanoma Therapeutics, Global, All Pipeline Products, Preclinical Phase, 2014 151
Melanoma Therapeutics, Global, All Pipeline Products, IND/CTA-filed Phase, 2014 157
Melanoma Therapeutics, Global, All Pipeline Products, Phase I, 2014 157
Melanoma Therapeutics, Global, All Pipeline Products, Phase II, 2014 160
Melanoma Therapeutics, Global, All Pipeline Products, Phase III, 2014 165
Melanoma Therapeutics, Global, All Pipeline Products, Pre-registration Phase, 2014 166
Melanoma Therapeutics Market, Global, Market Forecast, 2013-2020 166
Melanoma Therapeutics Market, US, Market Forecast, 2013-2020 166
Melanoma Therapeutics Market, Canada, Market Forecast, 2013-2020 167
Melanoma Therapeutics Market, UK, Market Forecast, 2013-2020 167
Melanoma Therapeutics Market, France, Market Forecast, 2013-2020 168
Melanoma Therapeutics Market, Germany, Market Forecast, 2013-2020 168
Melanoma Therapeutics Market, Italy, Market Forecast, 2013-2020 169
Melanoma Therapeutics Market, Spain, Market Forecast, 2013-2020 169
Melanoma Therapeutics Market, Japan, Market Forecast, 2013-2020 170
List of Abbreviations 183

On similar lines, has another and new 2015 research titled Global Melanoma Therapeutics Market 2015-2019 that forecasts the worldwide industry to grow at 15.4% CAGR to 2019. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of melanoma that are available in the market. The market is divided into four segments: CM, OM, MM, and Others. Companies like BMS, Merck, Roche, AB Science, Amgen, Bayer, Celgene, Daiichi Sankyo, Eisai, Galectin Therapeutics, GSK, Novartis, Pfizer, Vical and ZIOPHARM are mentioned in this research.

Explore more reports on the cancer therapeutics market at .

About Us: is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Connect with Us: 

G+ / Google Plus:



RSS / Feeds:

Ritesh Tiwari
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel:  +1-888-391-5441

SOURCE RnR Market Research